This is a summary of the European public assessment report (EPAR) for Tygacil. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tygacil.
Therapeutic Indication
Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: * Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections * Complicated intra\-abdominal infections (cIAI) Tygacil should be used only in situations where other alternative antibiotics are not suitable. Consideration should be given to official guidance on the appropriate use of antibacterial agents. appropriate use of antibacterial agents.
Therapeutic Area (MeSH)
ATC Code
J01AA12
ATC Item
N/A
Pharmacotherapeutic Group
Antibacterials for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| tigecycline | N/A | tigecycline |
EMA Name
Tygacil
Medicine Name
Tygacil
Aliases
N/ANo risk management plan link.
